One of the ongoing Phase I/II trials uses epidermal growth factor receptor 2 (HER2) CAR-T cells to treat advanced-stage ewing’s sarcoma (ES), osteosarcoma (OS), rhabdomyosarcoma (RMS), desmoplastic small round cell tumour (DSRC), and peripheral neuroectodermal tumour positive to the HER2 receptor after chemotherapy (NCT00902044). Here, ERBB2 is linked to epithelioid sarcoma.